Exelixis (EXEL) Tops Q3 EPS by 13c, Tops on Revenue; Offers FY24 Revenue Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Exelixis (EXEL) PT Raised to $29 at Stephens
October 30, 2024 6:27 AM EDTStephens analyst Sudan Loganathan raised the price target on Exelixis (NASDAQ: EXEL) to $29.00 (from $23.00) while maintaining a Equal Weight rating.
The analyst comments "EXEL reported 3Q24 financial results yesterday (10/29/2024) after market close and provided regulatory and business updates. Key highlights on the... More
Exelixis (EXEL) PT Raised to $38 at Citi
October 30, 2024 5:47 AM EDTCiti analyst David Lebowitz raised the price target on Exelixis (NASDAQ: EXEL) to $38.00 (from $31.00) while maintaining a Buy rating.
The analyst comments "Exelixis reported 3Q24 financial results, beating consensus on top-line revenue and GAAP EPS due to continued strength of cabozantinib. Total... More
